Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
01/07/2026 07:00 AM • Syndax Pharmaceuticals and the World Orphan Drug Alliance announced a collaboration to expand access to Revuforj (revumenib), a first-in-class menin inhibitor, through a Managed Access Program in regions including parts of Eurasia, Central and Southeast Europe, Israel, the Middle East, Turkey, Latin America, and Africa where the drug is not yet commercially available.
SNDX - The announcement demonstrates strategic expansion of Revuforj's market reach beyond the U.S., enabling access in multiple regions and supporting long-term goals to establish the drug as a standard of care globally. This partnership with WODA enhances the company's mission and market penetration without requiring independent infrastructure development.
Investing.com • Gurufocus